ALARIS Medical Announces SmartSite Plus Valve, the Newest Addition to the SmartSite Needle-Free System.Business Editors & Health/Medical Writers SAN DIEGO--(BW HealthWire)--April 17, 2002 ALARIS Medical Inc. (AMEX AMEX See: American Stock Exchange :AMI), through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , ALARIS Medical Systems Inc., today announced the full global market release of the SmartSite(R) Plus valve, the newest addition to the SmartSite(R) needle-free system. The SmartSite Plus valve features a positive displacement to help clear and maintain patients' catheters. Upon removal of a syringe, the SmartSite Plus valve automatically displaces a positive bolus bolus /bo·lus/ (bo´lus) 1. a rounded mass of food or pharmaceutical preparation ready to swallow, or such a mass passing through the gastrointestinal tract. 2. a concentrated mass of pharmaceutical preparation, e. helping to prevent blood backflow backflow /back·flow/ (-flo) reflux or regurgitation (1). pyelovenous backflow drainage from the renal pelvis into the venous system occurring under certain conditions of back pressure. into the catheter lumen. Blood backflow is a major cause of catheter occlusion, which is associated with increased hospital stays and increased expense. For an educational video about the SmartSite Plus valve visit http://www.alarismed.com/smartsiteplus. The SmartSite needle-free system allows healthcare institutions to comply with the "Needlestick Safety and Prevention Act," signed into Federal Law in November 2000, and addresses healthcare workers' safety concerns by allowing them to access IV lines without needles. Jake St. Philip, vice president and general manager of ALARIS Medical Systems' North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. Business Unit, said, "Adding the SmartSite Plus valve to our SmartSite needle-free system offers healthcare institutions a complete solution to the dangers of needlesticks, allowing them to standardize on one integrated needle-free system throughout their facility." About the SmartSite Needle-Free System The SmartSite needle-free system's ease of use and capless design set new standards for convenience, cost-control and needle-free compliance. In addition, the SmartSite system is latex-free, reducing the likelihood of allergic reactions. From a full line of administration sets that are compatible with ALARIS Medical Systems' infusion pumps, to gravity sets, extension sets and components, the SmartSite system provides a complete needle-free system. About Needle-Free Legislation Healthcare workers suffer from an estimated 590,000 needlestick injuries each year resulting in 35 U.S. workers per year contracting HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and an additional 2,400 infected with hepatitis B Hepatitis B Definition Hepatitis B is a potentially serious form of liver inflammation due to infection by the hepatitis B virus (HBV). It occurs in both rapidly developing (acute) and long-lasting (chronic) forms, and is one of the most common chronic and C annually. Federal OSHA OSHA n. Occupational Safety and Health Administration, a branch of the US Department of Labor responsible for establishing and enforcing safety and health standards in the workplace. data suggests the cost of needlestick treatment to be $1.3 to $2.3 billion, according to the Service Employees International Union (1998). The "Needlestick Safety and Prevention Act" is intended to increase protection for healthcare workers against needlestick injuries by requiring that healthcare facilities implement the use of "safer medical devices" to minimize accidental needlesticks. The legislation requires that frontline workers be involved in the evaluation, selection and implementation of new safety devices. The SmartSite needle-free system has a proven track record among clinicians and healthcare workers, with over 1,330 acute care hospitals nationwide utilizing the SmartSite technology. In addition to this federal initiative, as of January 2002, 21 states have passed needlestick prevention legislation and 6 states have bills pending. ALARIS Medical Inc., through its wholly owned operating company operating company A business that engages in transactions with outsiders. , ALARIS Medical Systems Inc., is a leading developer, manufacturer and provider of integrated intravenous infusion therapy and patient monitoring instruments and related disposables, accessories and services. ALARIS Medical's primary brands, ALARIS(R), IMED IMED International Medical Education Directory (R) and IVAC IVAC Islington Voluntary Action Council (England, UK) IVAC Insert Valid Access Card (satellite TV hacking) IVAC International Video & Audio Convention IVAC Idle Air Control Valve (R), are recognized throughout the world. ALARIS Medical's products are distributed in more than 120 countries worldwide. In addition to its San Diego world headquarters and manufacturing facility, ALARIS Medical also operates manufacturing facilities in Creedmoor, N.C.; Basingstoke, U.K.; and Tijuana, Mexico. Additional information on ALARIS Medical can be found at www.alarismed.com/. This news release contains forward-looking statements as defined in the Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Persons reading this release are cautioned that such forward-looking statements involve risks and uncertainties, including the effect of legislative and regulatory changes affecting the health care industry, the potential of increased levels of competition, technological changes, the dependence of ALARIS Medical upon the success of new products (including its proprietary Guardrails(TM) Safety Software and the MEDLEY(TM) Medication Safety System) and ongoing research and development efforts including obtaining regulatory approvals, restrictions contained in the instruments governing the Company's indebtedness, and the significant leverage to which the Company is subject. Such risk factors are detailed in the Securities and Exchange Commission filings of ALARIS Medical, Inc. and ALARIS Medical Systems, Inc., including Forms 10-K for the year ended December 31, 2001, and other filings. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion